Migraine Headache Misconceptions: Barriers to Effective Care

Pharmacotherapy

Volumn 24, Issue 5 I, 2004, Pages 638-648

  Wenzel, Richard ^a,b   Dortch, Marcus ^a   Cady, Roger ^c   Lofland, Jennifer H ^d   Diamond, Seymour ^a  

^a SAINT JOSEPH HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c HEADACHE CARE CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Migraine headache; Migraine misconceptions; Migraine therapy; Triptans

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ERROR; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; ECG ABNORMALITY; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MIGRAINE; PATHOGENESIS; PHARMACIST; SHORT SURVEY; SIDE EFFECT; SOCIETY; SYNCOPE; TACHYCARDIA; THORAX PAIN; UNITED STATES; WOLFF PARKINSON WHITE SYNDROME; WORKPLACE;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PREVALENCE; SEROTONIN AGONISTS;

EID: 2342622642     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.6.638.34751     Document Type: Short Survey

References (104)

1. World Health Organization. Headache disorders and public health. Geneva, Switzerland: Department of Mental Health and Substance Dependence, Noncommunicable Diseases and Mental Health Cluster, 2000.
2. International Headache Society. Classification and diagnosis for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
3. Lipton RB, Diamond SD, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American migraine study II. Headache 2001;41:638-45.
4. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache 2001;41:646-57.
5. Lipton RB, Stewart WF, Kolodner KB, Liberman JN. Epidemiology and patterns of health care use for migraine in the United States. Headache 1999;39:365-6.
6. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002;58:885-94.
7. Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002;42:501-9.
8. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache 2001;41:573-8.
9. Wenzel RG, Sarvis CA. Do butalbital-containing products have a role in the management of migraine? Pharmacotherapy 2002;22:1029-35.
10. Young WB, Siow HC. Should butalbital-containing products be banned? Yes. Curr Pain Headache Rep 2002;6:151-5.
11. Wenzel RG, Sarvis CA, Krause ML. Over-the-counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy 2003;23:494-505.
12. Wenzel RG, Lipton RB, Diamond ML, Cady R. Migraine therapy: a survey of pharmacists' knowledge, attitudes, and practice patterns. Presented at the 11th congress of the International Headache Society, Rome, Italy, September 13-16, 2003.
13. Wenzel R, Neidich M. Headache education in colleges of pharmacy. Ann Pharmacother 2002;36:612-14.
14. Edmeads J. The treatment of headache: a historical perspective. In: Gallagher RM, ed. Therapy for headache. New York: Marcel Dekker Inc., 1990:1-8.
15. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938;39:737-63.
16. Tunis MM, Wolff HG. Long-term observations of the reactivity of the cranial arteries in subjects with vascular headache of the migraine type. Arch Neurol Psychiatr 1953;70:551-7.
17. Goadsby PJ. Pathophysiology of headache. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's headache and other head pain, 7th ed. Oxford, England: Oxford University Press, 2001:57-72.
18. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-42.
19. Spierings ELH. Mechanisms of migraine headache: the human evidence. Headache & Pain 2003;14:11-16.
20. Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ. Brain-stem activation specific to migraine headache. Lancet 2001;357:1016-17.
21. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002;346:257-70.
22. Pietrobon D, Striessnig J. Neurobiology of migraine. Nature 2003;4:386-98.
23. Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993;5:159-77.
24. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience 2001;106:793-800.
25. Cady R, Schreiber C, Farmer K, Sheftell F. Primary headaches: a convergence hypothesis. Headache 2002;42:204-16.
26. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack. Brain 2000;123:1703-9.
27. Kaube H, Katsarava Z, Przywara S, Drepper J, Ellrich J, Diener HC. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 2002;58:1234-8.
28. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-24.
29. Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol 2000;15(suppl):28-35.
30. Marcus D. Central sensitization: an important factor in the pathogenesis of chronic headache. Headache & Pain 2003;14:19-23.
31. Burstein R. Differentiating effects of triptans on physiological trigeminovascular neurons reveal a mechanism of action critical for terminating migraine. Presented at the 45th annual scientific meeting of the American Headache Society, Chicago, IL, June 21, 2003.
32. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: results of the spectrum study. Headache 2000;40:792-7.
33. Hu X, Raskin NH, Cowan R, Markson LE, Berger ML. Treatment of migraine with rizatriptan: when to take the medication. Headache 2002;42:16-20
34. Pascual J, Cabarricas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31
35. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000;22:1035-48.
36. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine. Neurology 2003;60:935-40.
37. GlaxoSmithKline. Imitrex (sumatriptan) full prescribing information. Research Triangle Park, NC; 2001.
38. GlaxoSmithKline. Amerge (naratriptan) full prescribing information. Research Triangle Park, NC; 2001.
39. AstraZeneca Pharmaceuticals LP. Zomig (zolmitriptan) full prescribing information. Wilmington, DE; 2001.
40. Merck & Co. Maxalt (rizatriptan) full prescribing information. West Point, PA; 2001.
41. Pharmacia Corporation. Axert (almotriptan) full prescribing information. Chicago, IL; 2002.
42. Elan Biopharmaceuticals. Frova (frovatriptan) full prescribing information. Fairview, NJ; 2002.
43. Pfizer. Relpax (eletriptan) full prescribing information. New York, NY; 2003.
44. VanDenBrink A, van den Broek R, de Vries R, Saxena P. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan [abstr]. Cephalalgia 1999;A19:398.
45. VanDenBrink A, van den Broek R, de Vries R, Upton N, Parsons A, Saxena P. SB-220453 lacks vasoconstrictor activity in human isolated coronary artery and saphenous vein [abstr]. Cephalalgia 1999;A19:398.
46. Van den Broek R, VanDenBrink A, de Vries R, et al. Pharmacological analysis of contraction to eletriptan and sumatriptan in human isolated coronary artery and saphenous vein [abstr]. Cephalalgia 1999;A19:399.
47. Kaumann AJ, Frenken M, Posival H, Brown AM. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. Circulation 1994;90(3):1141-53.
48. Goline P, Piscone F, Benedict C, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med 1994;330:523-8.
49. Tousoulis D, Davies G, Tentolouris C, Apostolopoulos T, Kyriakides M, Toutouzas P. Effects of ketanserin on epicardial coronary arteries after coronary angioplasty in patients with stable angina. Eur Heart J 1994;15:922-7.
50. 2 receptor activation. Eur J Pharm 1989;161:91-4.
51. Nilsson T, Longmore J, Shaw D, et al. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharm 1999;372:49-56.
52. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993;87:401-5.
53. 1 agonist, sumatriptan. Aliment Pharmacol Ther 1999;13:927-36.
54. Welch K, Mathew N, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000;20:687-95.
55. O'Quinn S, Davis R, Gutterman D, Pait G, Fox A. Prospective large scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999;19:223-31.
56. Bomhof M, Heywood J, Pradalier A, Enahoro H, Winter P, Hassani H. Tolerability and efficacy of naratriptan tablets with long-term treatment. Cephalalgia 1998;18:33-7.
57. Edmeads J, Millson D. Tolerability profile of zolmitriptan (Zomig; 311c90), a novel dual central and peripherally acting 5HT-1b/1d agonist: international clinical experience based on >3000 subjects treated with zolmitriptan. Cephalalgia 1997;17(suppl 18):41-52.
58. Elkind A, McDaris H, Satin L, Keywood C. The cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease during a migraine attack. Presented at the 9th congress of the International Headache Society, Barcelona, Spain, June 22-26, 1999.
59. GlaxoSmithKline. Data on file. Research Triangle Park, NC; 2003.
60. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
61. Marcus DA. Establishing a standard of speed for assessing the efficacy of the serotonin agonists. Arch Neurol 2001;58:1056-8.
62. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75.
63. Sheftell RD, Fox AW, Weeks R, Tepper SJ. Differentiating the efficacy of 5HT-1bd agonists. Headache 2001;41:257-63.
64. Saper JR. What matters is not the difference between triptans, but the differences between patients. Arch Neurol 2001;58:1481-2.
65. Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol 2001;58:1479-80.
66. Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache. Neurology 2000;55:754-63.
67. Advisory Committee of the Primary Care Network. Patient-centered strategies for effective management of migraine. Springfield, MO: Primary Care Network 2000. Available from www.primarycarenet.org. Accessed March 2, 2003.
68. Lipton RB, Cady RK, Stewart WF, Wilks K, Hall C. Diagnostic lessons from the spectrum study. Neurology 2002;58(suppl 6):S27-31.
69. Lipton RB, Stewart WF, Cady R, et al. Sumatriptan for the range of headaches in migraine sufferers: results of the spectrum study Headache 2000;40:783-91.
70. Schreiber CP, Hutchinson S. Is physician-diagnosed or patient-described "sinus headache" actually migraine? Presented at the 44th annual scientific meeting of the American Headache Society, Seattle, WA, June 21-23, 2002.
71. Cady RK, Schreiber CP. Sinus headache or migraine? Neurology 2002;58(suppl 6):S10-14.
72. Blumenthal HJ. Headache and sinus disease. Headache 2001;41:883-8.
73. Ruoff GE. When sinus headache isn't sinus headache. Headache Q 1997;8:22-31.
74. Cortelli P, Dahlof C, Bouchard J, et al. A multinational investigation of the impact of subcutaneous sumatriptan. III. Workplace productivity and non-workplace activity. Pharmacoeconomics 1997;11(suppl 1):35-42.
75. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan. Arch Intern Med 1999;159:857-63.
76. Cohen JA, Beall DG, Miller DW, Beck A, Pait G, Clements BD. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996;28:171-7.
77. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace: the impact of headaches in the workplace. 1997;39:320-7.
78. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and low labour costs of migraine headaches in the US. Pharmacoeconomics 1992;2:2-11.
79. Stang P, Cady R, Batenhorst A, Hoffman L. Workplace productivity: a review of the impact of migraine and its treatment. Pharmacoeconomics 2001;19:231-44.
80. Ferrari M. The economic burden of migraine to society. Pharmacoeconomics 1998;13:667-77.
81. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813-18.
82. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992;156:1273-8.
83. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache 1994;34:319-28.
84. Lofland J, Pizzi L, Frick KD. A review of health-related lost workplace productivity instruments. Pharmacoeconomics 2004;22(3):165-84.
85. Van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care: the health and labor questionnaire. Int J Technol Assess Health Care 1996;12:405-15.
86. Van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel BC, Rutten FF. Societal perspective on the burden of migraine in the Netherlands. Pharmacoeconomics 1995;7:170-9.
87. Davies GM, Santanello N, Gerth W, Lerner D, Block GA. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 1999;19:497-502.
88. Lerner D, Amick BC, Malspeis S, et al. The migraine work and productivity loss questionnaire: concepts and design. Qual Life Res 1999;8:699-710.
89. Lerner D, Amick BC, Rogers WH, Malspeis S, Bungay K, Cynn D. The work limitations questionnaire. Med Care 2001;39:72-85.
90. Lerner D, Reed JI, Massarotti E, Wester LM, Burke TA. The work limitations questionnaire's validity and reliability among patients with osteoarthritis. J Clin Epidemiol 2002;55:197-208.
91. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
92. Margaret Reilly. Health outcomes research. Available from www.reillyassociates.net. Accessed February 5, 2002.
93. Jacobson GP, Ramadan NM, Aggarwal SK, Newman CW. The Henry Ford Hospital headache disability inventory (HDI). Neurology 1994;44:837-42.
94. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form for measuring headache impact: the HIT-6. Qual Life Res 2003;12(8):963-74.
95. Lipton RB, Stewart WF, Stone A, Lainez M, Sawyer J. Stratified care vs step care strategies for migraine: the disability in strategies of care (DISC) study - a randomized trial. JAMA 2000;284:2599-605.
96. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 2001;56:S20-8.
97. Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine. Pharmacoeconomics 2002;20:91-100.
98. Anonymous. OTC products: a study of pharmacists' recommendations. Pharm Times October 2001;(suppl):10-30.
99. Anonymous. OTC products: a study of pharmacists' recommendations. Pharm Times September 2000;(suppl): 18-34.
100. Wenzel R. Triptan quantity limits [letter]. J Manag Care Pharm 2002;8:182-4.
101. 1 agonists and dihydroergotamine nasal spray. J Manag Care Pharm 2003;9:335-45.
102. Lipton RB, Cady RK, Stewart WF, Wilks K, Hall C. Diagnostic lessons from the spectrum study. Neurology 2002;58(suppl 6):S27-31.
103. Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic options. Ann Pharmacother 1999;33:61-72.
104. Sheftell FD, Tepper S. New paradigms in the recognition and acute treatment of migraine. Headache 2002;42:59-69.